The aim of this study was to analyse the outcome of patients with rheumatoid arthritis (RA) treated with infliximab. Thirty-one patients (3 male, 28 female), aged 50 years (range 22-67 years), treated in a single institution between 2001-2003 were included. For the purpose of this study, RA activity was analysed at baseline, after 23 weeks (i.e. after 5 infusions), and after 54 weeks (i.e. after 9 infusions). Twenty-one (68%) patients achieved good response according to EULAR criteria after both 23 and 54 weeks of therapy. None of the patients who failed to respond after 23 weeks responded after 54 weeks. None of the analysed factors (age, sex, disease duration, number of preceding disease-modifying anti-rheumatic drugs) was found to influence the probability to achieve good response. Our results indicate high efficacy of infliximab in the treatment of RA. They also suggest that the treatment protocol could further be rationalised.